Immunotherapy

30 March -1 April 2020 | Business Design Centre London

 

 

2000+
Attendees
700+
1-2-1 Meetings
300+
Speakers
100+
Exhibitors
12
Streams

 

 

Immunotherapy

IMMUNOTHERAPY, Tuesday 31 March 2020

CONFERENCE DAY 1 - TUESDAY 31st March 2020

Opening Keynotes Day 1 – CAR-T & Immunotherapy focus

08:45

Welcome – Jessica Robinson, Project Director, Advanced Therapies 2020, Terrapinn

Prasad Adusumilli
09:00

Keynote presentaton: Autologous Mesothelin-targeting CAR-T to tackle solid tumours in the clinic

  • The presentation will highlight results to date of mesothelin-targeted CAR T-cell clinical trial results
  • Advances in preclinical research of CAR T-cell therapy for solid tumors will be presented
  • Novel strategies for overcoming hurdles to solid tumor CAR T-cell therapy will be discussed
Panel discussion
Bradley Campbell
10:00

Importance of patient focus in developing gene therapy for rare diseases

10:20

Morning Coffee Break

Martin Pule
11:20

Keynote presentation: War in the Blood - the latest in the front line of CAR-T clinical research

Mark Sawicki
11:40

Effective Integration Strategies Through a Compliance Unified Ecosystem (CUE)

  • Systems Integration continues to be a major issue in the production and distribution of Advanced Therapies
  • Well-defined strategies for the integration of independent informatics platforms will be critical for future standardization and workflow optimization
  • Cryoport’s Compliance Unified Ecosystem (CUE) is driving standard practices for systems integration in the industry
round tables
12:00

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for you

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
Frank Hecht

Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH

10. Exploring the crossover between human and veterinary applications for stem cells
Joanna Miller

Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences

15. Industry-no profit alliances: how to optimize synergies
Elena Beltrami

Elena Beltrami, Business Development Manager, Fondazione Telethon

16. Industrialisation of ATMPs
Mark Lowdell

Mark Lowdell, Chief Scientific Officer, Inmunebio

17. How companies can interact with the regulator and various pitfalls to be aware of
John Johnston

John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency

19. Roundtable available
2. Physiological conditions and analytical and monitoring tools for 3D cell cultivations
Cornelia Kasper

Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, BOKU

21. Neurological applications for ATMPs
John Isaac

John Isaac, Senior Director, External Scientific Innovation And Neuroscience, Johnson & Johnson

22. Development of regenerative medicines for cardiovascular indications
David Mazzo

David Mazzo, Chief Executive Officer, Caladrius Biosciences

3. Ensuring safe delivery to patients and fast time-to-market of advanced therapies - How to address challenges of drug administration, fill & finish, packaging & stability?
Diana Lober

Diana Lober, Product Manager, Schott AG

5. Considerations for manufacture scale-up from academia to commercial manufacturing
Johannes Van Der Loo

Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia

7. Reserved for Fujifilm Diosynth Biotechnology
13:00

Lunch

IMMUNOTHERAPY

Precision medicine for immunotherapy

Dr Roy Baynes
IMMUNOTHERAPY
14:20

PD-1 antibodies are transforming cancer therapy both as mono- and in combination

  • PD-1 antibody activity in monotherapy may be enriched with precision medicine tools.
  • Precision medicine may help define resistance biology and enable rational combinations.
  • Certain combinations (e.g. chemotherapy or TKIs + PD-1 antibodies) may be broadly active without regard for biomarker-based selection.
Igor Rudychev
IMMUNOTHERAPY
14:40

From big patient-level data to actionable insights and answering right business questions in oncology

  • How Patient-Level data can help us to solve business questions from Advanced Therapies
  • Oncology case studies
  • How to optimize the business with data driven insights
Cynthia Bamdad
IMMUNOTHERAPY
15:00

1st-in-Human CAR T Targets MUC1 Cleavage Product Expressed on Solid Tumors

  • 1st-in-Human Trial for metastatic breast cancer open at the Fred Hutchinson Cancer Research Center.
  • huMNC2-CAR44 recognizes a cancer-specific MUC1 cleavage product called MUC1* (muk 1 star).
  • Antibody huMNC2 recognizes a conformational epitope formed when MUC1 is cleaved to MUC1* by an enzyme that is overexpressed in most solid tumors
Cynthia Bamdad, Chief Executive Officer, Minerva Biotechnologies Corp
Giuseppe Mazza
IMMUNOTHERAPY
15:20

Engineered tumor micro- environment using human extracellular matrix for modelling hot and cold tumours

Hans S Keirstead
IMMUNOTHERAPY
15:40

Novel immunotherapy targeting tumor initiating cells

  • 72% 2-year survival, 54% 5-year survival in stage 3 recurrent and stage 4 cancer
  • 96% manufacturing success rate
  • Extremely low cost of goods
Mangala Srinivas
IMMUNOTHERAPY
16:00

Customisable, multimodal imaging agents applied to the optimisation of cell therapy biodistribution and pharmacokinetics

16:20

Afternoon Break

Panel discussion
IMMUNOTHERAPY
17:20

Panel discussion: Precision medicine for immunotherapy

  • Using biomarkers and diagnostics to start correlating success rates in immunotherapy: how to know when to apply these
  • Which is more important: stratification of patients using biomarkers or identifying the correct cells for a specific application?
  • Gene editing therapeutics
18:00

Close of Conference for the day - Please join us for an evening drinks reception

last published: 04/Jun/20 09:25

IMMUNOTHERAPY, Wednesday 1 April 2020

CONFERENCE DAY 1 - WEDNESDAY 1st April 2020

Opening Keynotes Day 2 — The latest science in gene therapy and gene editing

Federico Mingozzi
09:00

Gene therapy 2.0: New clinical data, therapeutic applications and next generation technologies

  • Latest updates on LUXTURNA studies to treat blindness, haemophilia and rare disease
  • Tackling the challenges of viral gene therapies i.e. immunogenicity
  • Developing the next generation of gene therapies, what does the future hold?
Steve Kanner
09:20

Next-generation gene editing technology for allogeneic immune cell therapeutics

  • Next-generation CRISPR-Cas9 technology
  • Significantly enhanced editing specificity
  • Editing in immune cells for generation of functionally tuned therapeutics
Amy Pooler, Director, Neuroscience, Sangamo Theraputics
09:40

Repairing the human genome with designed zinc finger editing reagents

  • Overview of Sangamo’s zinc finger protein gene editing technology, including new innovations that facilitate specificity, precision, and gene editing efficiency
  • Will address specific examples of defined therapeutic applications including the generation of reagents suitable for use in tauopathies, Huntington’s disease, and lysosomal storage diseases
Frederic Chereau
10:00

In vivo gene editing paediatric patients with rare diseases

10:20

Networking Refreshments

IMMUNOTHERAPY

Immuno-oncology

David Pauza
IMMUNOTHERAPY
11:20

At the intersection of genetic medicine and immunotherapy: Clinical experience with a cell and gene therapy for HIV disease

David Blakey
IMMUNOTHERAPY
12:00

Small activating RNAs as a novel approach for immunotherapy

  • Small activating RNAs can be designed to a wide range of targets to activate gene transcription
  • MiNA Therapeutics’lead saRNA to CEBPA has demonstrated proofof concept in the clinic
  • Novel saRNAs have been designed to specifically up-regulated immune targets for cancer immunotherapy
13:00

Neworking Lunch

16:00

Networking refreshments

18:00

Close of conference

last published: 04/Jun/20 09:25